Literature DB >> 32112978

Inhibitory effects of ceramide kinase on Rac1 activation, lamellipodium formation, cell migration, and metastasis of A549 lung cancer cells.

Satoshi Tomizawa1, Mizuki Tamori1, Ai Tanaka1, Naoya Utsumi1, Hiromi Sato2, Hiroto Hatakeyama2, Akihiro Hisaka2, Takafumi Kohama3, Kazuyuki Yamagata1, Takuya Honda1, Hiroyuki Nakamura4, Toshihiko Murayama1.   

Abstract

Ceramide kinase (CerK) phosphorylates ceramide to ceramide-1-phosphate (C1P), a bioactive sphingolipid. Since the mechanisms responsible for regulating the proliferation and migration/metastasis of cancer cells by the CerK/C1P pathway remain unclear, we conducted the present study. The knockdown of CerK in A549 lung and MCF-7 breast cancer cells (shCerK cells) increased the formation of lamellipodia, which are membrane protrusions coupled with cell migration. Mouse embryonic fibroblasts prepared from CerK-null mice also showed an enhanced formation of lamellipodia. The overexpression of CerK inhibited lamellipodium formation in A549 cells. The knockdown of CerK increased the number of cells having lamellipodia with Rac1 and the levels of active Rac1-GTP form, whereas the overexpression of CerK decreased them. CerK was located in lamellipodia after the epidermal growth factor treatment, indicating that CerK functioned there to inhibit Rac1. The migration of A549 cells was negatively regulated by CerK. An intravenous injection of A549-shCerK cells into nude mice resulted in markedly stronger metastatic responses in the lungs than an injection of control cells. The in vitro growth of A549 cells and in vivo expansion after the injection into mouse flanks were not affected by the CerK knockdown. These results suggest that the activation of CerK/C1P pathway has inhibitory roles on lamellipodium formation, migration, and metastasis of A549 lung cancer cells.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Cell movement; Ceramide-1-phosphate; Sphingolipids

Year:  2020        PMID: 32112978     DOI: 10.1016/j.bbalip.2020.158675

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Biol Lipids        ISSN: 1388-1981            Impact factor:   4.698


  6 in total

Review 1.  Sphingolipid Metabolism and Signaling in Lung Cancer: A Potential Therapeutic Target.

Authors:  Mengmeng Lin; Yingying Li; Shiyuan Wang; Bo Cao; Chunyu Li; Guohui Li
Journal:  J Oncol       Date:  2022-06-28       Impact factor: 4.501

2.  CEBPγ facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation.

Authors:  Hanxiao Shi; Atsuko Niimi; Toshiyuki Takeuchi; Kazuya Shiogama; Yasuyoshi Mizutani; Taisuke Kajino; Kenichi Inada; Tetsunari Hase; Takahiro Hatta; Hirofumi Shibata; Takayuki Fukui; Toyofumi Fengshi Chen-Yoshikawa; Kazuki Nagano; Takashi Murate; Yoshiyuki Kawamoto; Shuta Tomida; Takashi Takahashi; Motoshi Suzuki
Journal:  Cancer Sci       Date:  2021-05-04       Impact factor: 6.716

Review 3.  Cholesterol and Sphingolipid Enriched Lipid Rafts as Therapeutic Targets in Cancer.

Authors:  Michela Codini; Mercedes Garcia-Gil; Elisabetta Albi
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

4.  Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple-negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways.

Authors:  Shan Zhu; Yulin Xu; Lijun Wang; Shichong Liao; Yuan Wang; Manman Shi; Yi Tu; Yurong Zhou; Wen Wei
Journal:  Cancer Cell Int       Date:  2021-01-11       Impact factor: 5.722

Review 5.  Implication of Ceramide Kinase/C1P in Cancer Development and Progression.

Authors:  Laura Camacho; Alberto Ouro; Ana Gomez-Larrauri; Arkaitz Carracedo; Antonio Gomez-Muñoz
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

Review 6.  The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance.

Authors:  Run-Ze Li; Xuan-Run Wang; Jian Wang; Chun Xie; Xing-Xia Wang; Hu-Dan Pan; Wei-Yu Meng; Tu-Liang Liang; Jia-Xin Li; Pei-Yu Yan; Qi-Biao Wu; Liang Liu; Xiao-Jun Yao; Elaine Lai-Han Leung
Journal:  Front Oncol       Date:  2022-07-27       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.